Clinical trials: Methylphenidate
Attention Deficit Hyperactivity Disorder
Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety and effectiveness of OROS® Methylphenidate HCl (a central nervous system stimulant) in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00269815
- Testing
- methylphenidate HCl
- Sponsor
- Alza Corporation, DE, USA
Healthy
Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents
This is a study in adults to assess the sensitivity of Project: EVO Monitor cognitive measurements to two short-acting cognitively active pharmacological agents.
- Trial name
- NCT02822937
- Testing
- Methylphenidate, Triazolam, Project: EVO
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Akili Interactive Labs, Inc.
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy
The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.
- Trial name
- NCT00485550
- Testing
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02450890
- Where
- 4 sites in Taiwan
- Volunteers
- 114 people
- Sponsor
- Orient Pharma Co., Ltd.
Attention Deficit Hyperactivity Disorder
Characterization of Dermal Reactions in Pediatric Patients With ADHD Using DAYTRANA
This is a study designed to characterize the dermal response of DAYTRANA. Subjects will visit the study site over a period of approximately 14 weeks.
- Trial name
- NCT00434213
- Testing
- Daytrana
- Where
- 29 sites in United States
- Volunteers
- 309 people
- Sponsor
- Noven Therapeutics
Attention Deficit Disorder With Hyperactivity
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
- Trial name
- NCT00151983
- Testing
- Methylphenidate Transdermal System
- Where
- 18 sites in United States
- Volunteers
- 175 people
- Sponsor
- Noven Therapeutics
Attention Deficit Disorder With Hyperactivity
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to compare the ADHD symptom response of adults with ADHD treated with OROS MPH to those treated with placebo.
- Trial name
- NCT00937040
- Testing
- OROS MPH, OROS MPH Tablets
- Volunteers
- 357 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
ADHD
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
The purpose of this study is to compare the safety and efficacy of two doses of dexmethylphenidate to two doses of an approved, long-acting, marketed medication for ADHD (MPH) and placebo in children ages 6-12 diagnosed with ADHD.
- Trial name
- NCT00141063
- Testing
- Focalin XR
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Novartis
Cerebrovascular Accident, Transient Ischemic Attack
Safety Study of Atomoxetine and Cerebrovascular Outcomes
Using a proprietary insurance health claims database, Eli Lilly and Company has contracted with an external party to conduct a retrospective cohort study of health claims for the time period from 1 January 2003 through 31…
- Conditions
- Cerebrovascular Accident, Transient Ischemic Attack, ADHD
- Trial name
- NCT00634439
- Testing
- atomoxetine, Stimulants, No intervention (general population)
- Where
- United States
- Volunteers
- 72,000 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
The primary objective of this study is to evaluate the long-term safety and tolerability of methylphenidate hydrochloride extended-release capsules (Aptensio XR®) in children aged 4-5 years who have been diagnosed with…
- Trial name
- EF004 (NCT02677519)
- Testing
- Aptensio XR
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
- Trial name
- NCT02168127
- Testing
- Drug: PRC-063, PRC-063
- Where
- 35 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Cancer-related Fatigue
Methylphenidate Treatment of Cancer-Related Fatigue
The purpose of this randomized controlled clinical trial is to investigate the efficacy and safety of methylphenidate in patients with fatigue caused by cancer.
- Trial name
- EMF (NCT00758407)
- Testing
- Methylphenidate hydrochloride
- Where
- 6 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Attention Deficit Disorder With Hyperactivity
A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD
This randomized, double-blind, flexible-dose, placebo-controlled, parallel group study is designed to evaluate Aptensio XR® compared to placebo in preschool age children with ADHD.
- Trial name
- EF003 (NCT02683265)
- Testing
- Aptensio XR
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME)
The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome
The Synergy Trial will evaluate the safety and efficacy of a currently available medication (methylphenidate hydrochloride) combined with a CFS-specific dietary supplement (CFS Nutrient Formula) to treat Chronic Fatigue Syndrome…
- Trial name
- NCT01966276
- Testing
- Methyl-P plus Nutrient Formula
- Where
- 4 sites in United States
- Volunteers
- 134 people
- Sponsor
- K-PAX Pharmaceuticals, Inc.
ADHD
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
- Trial name
- NCT00501293
- Testing
- Methylphenidate Transdermal System
- Where
- 32 sites in United States
- Volunteers
- 163 people
- Sponsor
- Noven Therapeutics
Attention Deficit Disorder With Hyperactivity
An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the efficacy, tolerability and effects of Osmotic Release Oral System (OROS) methylphenidate hydrochloride (HCl) on learning skill changes in Korean participants with Attention-Deficit…
- Trial name
- NCT01060150
- Testing
- OROS Methylphenidate HCl
- Volunteers
- 115 people
- Sponsor
- Janssen Korea, Ltd., Korea
Attention Deficit Hyperactivity Disorder
Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)
This study will assess the frequency of chromosomal abnormalities measured in circulating lymphocytes in treatment-naive children with Attention Deficit Hyperactivity Disorder (ADHD) treated for 3 months with either extended…
- Trial name
- NCT00409708
- Testing
- Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Novartis
Attention Deficit Hyperactivity Disorder
Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD
The purpose of the study is to compare atomoxetine hydrochloride and methylphenidate hydrochloride in pediatric patients with ADHD.
- Trial name
- NCT00486083
- Testing
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride
- Where
- 3 sites in China, Mexico and 1 more
- Volunteers
- 330 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD
Study designed to evaluate the safety and efficacy of MTS compared to placebo with reference to CONCERTA® in pediatric subjects diagnosed with ADHD.
- Trial name
- NCT00444574
- Testing
- Methylphenidate Transdermal System, Concerta
- Volunteers
- 282 people
- Sponsor
- Noven Therapeutics
Attention Deficit Disorder With Hyperactivity
Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD
This study will assess the efficacy, duration of effect, tolerability and safety of 4- and 6- hour wear times of SPD485 in 6-12 year old subjects diagnosed with ADHD.
- Trial name
- NCT00151970
- Testing
- Methylphenidate Transdermal System, Concerta
- Volunteers
- 128 people
- Sponsor
- Noven Therapeutics